3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 3
1
Status
Recruiting
2
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
CNS
1
Conditions
Breast Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
pembrolizumab
109
Cyclophosphamide
89
fludarabine
70
Carboplatin
57
Injections
56
Bevacizumab
49
Specimen Handling
43
Gemcitabine
41
Magnetic Resonance Spectroscopy
40
Paclitaxel
39
Nivolumab
38
venetoclax
36
Dexamethasone
35
Cisplatin
34
Biopsy
34
Temozolomide
31
Docetaxel
29
Capecitabine
27
atezolizumab
26
Oxaliplatin
26
Fluorouracil
26
Pemetrexed
24
Irinotecan
24
Azacitidine
24
abemaciclib
23
toripalimab
22
Fulvestrant
22
fludarabine phosphate
21
Rituximab
21
Leucovorin
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recruiting
×
RAD1901
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled
NCT07198724
2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2
Recruiting
65 enrolled